Search Results - "de Jongh, F.E."

Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group by Hamaker, M.E, Seynaeve, C, Wymenga, A.N.M, van Tinteren, H, Nortier, J.W.R, Maartense, E, de Graaf, H, de Jongh, F.E, Braun, J.J, Los, M, Schrama, J.G, van Leeuwen-Stok, A.E, de Groot, S.M, Smorenburg, C.H

“…Abstract Aim To evaluate the association between baseline comprehensive geriatric assessment (CGA) or the Groningen Frailty Indicator (GFI) and toxicity in…”
Get full text

Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients by Mostert, B., Sieuwerts, A.M., Kraan, J., Bolt-de Vries, J., van der Spoel, P., van Galen, A., Peeters, D.J., Dirix, L.Y., Seynaeve, C.M., Jager, A., de Jongh, F.E., Hamberg, P., Stouthard, J.M.L., Kehrer, D.F.S., Look, M.P., Smid, M., Gratama, J.W., Foekens, J.A., Martens, J.W.M., Sleijfer, S.

“…CTC characterization by a 16-gene profile identified from previously published CTC-specific genes detected poor prognosis metastatic breast cancer (MBC)…”
Get full text

1883 Prevalence and prognostic impact of HER2-positive circulating tumor cells in metastatic breast cancer patients with HER2-negative primary tumors by Beije, N, Onstenk, W, Kraan, J, Hamberg, A.P, Dirix, L.Y, Peeters, D.J, De Jongh, F.E, Jager, A, Seynaeve, C.M, Van, N.M, Martens, J.W.M, Sleijfer, S

Get full text

249 Feasibility and Toxicities Associated with PEG Doxo Versus Capecitabine as First-line Chemotherapy in Elderly Metastatic Breast Cancer (MBC) Patients; Results From the Randomized OMEGA Study of the Dutch Breast Cancer Trialists’ Group (BOOG) by Seynaeve, C, van Tinteren, H, Wymenga, A.N.M, Nortier, J.W.R, Maartense, E, de Jongh, F.E, de Graaf, H, de Groot, S.M, Braun, J.J

Get full text

654 Predictive value of a dextromethorphan phenotyping test for endoxifen exposure by de Graan, A.J, Teunissen, S.F, de Vos, F.Y, Loos, W.J, van Schaik, R.H, de Jongh, F.E, Seynaeve, C, Verweij, J, Beijnen, J.H, Mathijssen, R.H

Get full text

5068 Cardiac safety of non-pegylated liposomal doxorubicin in combination with docetaxel as 1st line treatment in locally advanced or metastatic HER2 negative breast cancer (MYOTAX study) by van Warmerdam, L.J.C, Schiphorst, P.P, Nieboer, P, Dercksen, M.W, Pruijt, J.F.M, de Jongh, F.E, Creemers, G.J.M

Get full text

Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study by Goey, K.K.H., Elias, S.G., van Tinteren, H., Laclé, M.M., Willems, S.M., Offerhaus, G.J.A., de Leng, W.W.J., Strengman, E., ten Tije, A.J., Creemers, G.-J. M., van der Velden, A., de Jongh, F.E., Erdkamp, F.L.G., Tanis, B.C., Punt, C.J.A., Koopman, M.

“…The phase 3 CAIRO3 study showed that capecitabine plus bevacizumab (CAP-B) maintenance treatment after six cycles capecitabine, oxaliplatin, and bevacizumab…”
Get full text

A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG by Smorenburg, C.H., de Groot, S.M., van Leeuwen-Stok, A.E., Hamaker, M.E., Wymenga, A.N., de Graaf, H., de Jongh, F.E., Braun, J.J., Los, M., Maartense, E., van Tinteren, H., Nortier, J.W.R., Seynaeve, C.

“…Prospective data on chemotherapy for elderly patients with metastatic breast cancer (MBC) remain scarce. We compared the efficacy and safety of first-line…”
Get full text

Dose-dense cisplatin/paclitaxel: a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer by de Jongh, F.E, de Wit, R, Verweij, J, Sparreboom, A, van den Bent, M.J, Stoter, G, van der Burg, M.E.L

“…A randomised phase I/II trial with weekly cisplatin 70 mg/m2 (days 1, 8, 15, 29, 36, 43) in combination with escalating doses of paclitaxel either 4-weekly or…”
Get full text

Dose-dense cisplatin/paclitaxel by de Jongh, F.E, de Wit, R, Verweij, J, Sparreboom, A, van den Bent, M.J, Stoter, G, van der Burg, M.E.L

Get full text